Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 22, 2026
Exact Sciences to participate in September investor conference
06:00am, Thursday, 01'st Sep 2022
MADISON, Wis. , Sept. 1, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate
Here's Why You Should Retain Exact Sciences (EXAS) Now
01:32pm, Wednesday, 24'th Aug 2022
Investors are optimistic about Exact Sciences' (EXAS) better-than-expected results and robust Cologuard volumes.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
08:10am, Wednesday, 24'th Aug 2022
The best-known growth ETF money manager is making moves. Let's check out her shopping list.
3 Growth Stocks That Could Soar 51% to 385%, According to Wall Street
06:03am, Monday, 22'nd Aug 2022
Expectations for these stocks are still sky high.
3 Growth Stocks That Could Soar 35% to 84%, According to Wall Street
06:08am, Saturday, 20'th Aug 2022
Analysts still have great expectations for these beaten-down stocks.
5 Top Stocks Cathie Wood Bought This Week
05:02pm, Friday, 05'th Aug 2022
Cathie Wood's exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%.
Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down
01:32pm, Wednesday, 03'rd Aug 2022
Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.
Exact Sciences Stock Falls After Earnings. Here's What Wall Street Is Saying.
12:54pm, Wednesday, 03'rd Aug 2022
June quarter sales were $522 million, representing 26% growth if one backs out last year's sales bump from Covid-19 tests
Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q2 2022 Results - Earnings Call Transcript
07:16pm, Tuesday, 02'nd Aug 2022
Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Megan Jones - Senior Director, Investor Relations Kevin Conroy - Chairman & Ch
Exact Sciences to participate in August investor conference
06:00am, Monday, 01'st Aug 2022
MADISON, Wis. , Aug. 1, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate
Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?
01:56pm, Monday, 25'th Jul 2022
Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.
6 Cathie Wood Stocks to Buy on the Dip
11:21am, Thursday, 14'th Jul 2022
As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers. The post 6 Cathie Wood Stocks to Buy on the Dip appeared firs
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:15am, Thursday, 14'th Jul 2022
The best-known growth ETF money manager is making moves. Let's check out her shopping list.
2 Cancer-Focused Stocks That Could Soar, According to Wall Street
11:15am, Wednesday, 13'th Jul 2022
Let's look beyond short-term price targets analysts assign.
Exact Sciences schedules second quarter 2022 earnings call
06:00am, Friday, 08'th Jul 2022
MADISON, Wis. , July 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its sec
